Moderna's mRNA Flu Vaccine to Get FDA Panel Review The news that Moderna's experimental mRNA flu shot will be reviewed by an FDA advisory panel next month has sent ripples through the healthcare community, sparking questions about the efficacy of this new approach to vaccine development.
The move marks a significant departure from the usual procedure and reflects growing concerns about the agency's handling of vaccine approvals.
The FDA's decision to review Moderna's MFLUSIVA flu vaccine is a test case for the agency's new regulatory strategy.